Brand Name(s):Vepesid

Indication:Small cell carcinoma of the bronchus, lymphomas & testicular cancer



Review Date:Aug-26

NICE TA638 1.1Atezolizumab with carboplatin and etoposide is recommended as an option for untreated extensive-stage small-cell lung cancer in adults, only if:

they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and

the company provides atezolizumab according to the commercial arrangement.

1.2When using ECOG performance status, healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect ECOG performance status and make any adjustments they consider appropriate.

1.3These recommendations are not intended to affect treatment with atezolizumab that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. …………………………NICE NG52
Non-Hodgkin’s lymphoma: diagnosis and management
July 2016
Doctors, nurses, pharmacists and their staff must be made aware that the prescribing, dispensing and administering of oral
anti-cancer medicines should be carried out and monitored to the same standard as injected therapy. This requires that:
* Healthcare organisations should prepare local policies and procedures that describe the safe use of these oral
* Treatment should be initiated by a cancer specialist.
* All oral anti-cancer medicines should be prescribed only in the context of a written protocol and treatment plan.
* Non-specialists who prescribe or administer on-going oral anti-cancer medication should have ready access to
appropriate written protocols and treatment plans including guidance on monitoring and treatment of toxicity.
* Staff dispensing oral anti-cancer medicines should be able to confirm that the prescribed dose is appropriate for the
patient, and that the patient is aware of the required monitoring arrangements, by having access to information in the
written protocol and treatment plan from the hospital where treatment is initiated and advice from a pharmacist with
experience in cancer treatment in that hospital.
* Patients should be fully informed and receive verbal and up-to-date written information about their oral anticancer
therapy from the initiating hospital. This information should include contact details for specialist advice, which can be
shared with non-specialist practitioners. Written information, including details of the intended oral anti-cancer regimen,
treatment plan and arrangements for monitoring, taken from the original protocol should be given to the patient. When
shared with pharmacists and dispensing staff, this would enable the above dispensing requirements to be satisfied.
* Full use should also be made of NHS cancer centre web sites to provide information for healthcare staff, patients and carers to ensure the safe use of oral anti-cancer medicines.

Risks of incorrect dosing of oral anti-cancer medicines – NPSA January 2008